Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2336 studies found for:    paclitaxel
Show Display Options
Rank Status Study
1 Active, not recruiting Hepatic Arterial Infusion (HAI) of Abraxane
Conditions: Liver Cancer;   Advanced Cancers;   Solid Tumors
Interventions: Drug: HAI Abraxane;   Procedure: Hepatic Artery Catheter;   Drug: IV Abraxane
2 Completed Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib
3 Recruiting Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225;   Drug: Gemcitabine;   Drug: nab-paclitaxel
4 Unknown  Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
5 Completed Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Placebo
6 Recruiting A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Condition: Advanced Cancer
Interventions: Drug: AZD2014 3 on/4 off & weekly paclitaxel;   Drug: AZD2014 2 on/5 off & weekly paclitaxel
7 Terminated
Has Results
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Neoplasm Metastasis
Interventions: Drug: ABI-007 (Abraxane);   Drug: bevacizumab
8 Recruiting Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: ABI-007;   Drug: Ipilimumab;   Behavioral: Phone Call
9 Not yet recruiting Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubenemia
Conditions: Pancreatic Neoplasms;   Cholestasis
Interventions: Drug: nab-paclitaxel;   Drug: Gemcitabine
10 Completed HAI Abraxane With Gemcitabine and Bevacizumab
Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Filgrastim
11 Recruiting Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane  (Induction);   Drug: Carboplatin (Induction);   Drug: Abraxane (Maintenance);   Other: Best Supportive Care (Maintenance)
12 Recruiting BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin;   Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin;   Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1);   Drug: BKM120, Paclitaxel + Carboplatin
13 Withdrawn A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
14 Active, not recruiting
Has Results
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Condition: Malignant Solid Tumor
Interventions: Biological: ramucirumab (IMC-1121B);   Drug: paclitaxel
15 Recruiting Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: nab-paclitaxel
16 Completed Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine plus nab-paclitaxel
17 Recruiting Safety and Efficacy Study of Abraxane Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Abraxane;   Drug: Gemcitabine
18 Not yet recruiting Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: nab-paclitaxel IV;   Drug: CC-486
19 Terminated Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: Intraperitoneal tgDCC-E1A;   Drug: Paclitaxel
20 Active, not recruiting Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years